Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Trial details
- Registry ID
- NCT06500273
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLNCT06500273 | Allogene Therapeutics | Phase 2 | Recruiting | 2027-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |